Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events (6 weeks' · primary Raynaud's phenomenon
Prostagladin/prostacyclin analogues may leads to higher adverse events (6 weeks' compared with placebo (low certainty).
1 finding from 1 review
Adverse events (3 weeks' · primary Raynaud's phenomenon
1 finding from 1 review
no estimate extracted
1 study · 8 participants
GRADE not reported
Any other adverse events · women undergoing assisted reproduction
It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Serious adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
Alopecia · healthy men
Selenium leads to higher adverse events: alopecia compared with placebo (high certainty).
1 finding from 1 review
adverse events(16 weeks) · depression in adults
1 finding from 1 review
Number of adverse events · Adults over 18 years presenting with a single tooth with a clinical diagnosis of irreversible pulpitis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events ( · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Adverse events (serious) · carpal tunnel syndrome
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Adverse events incidence · patients with stable angina pectoris
It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).
1 finding from 1 review
Adverse events incidence · patients with stable angina pectoris
Ranolazine (add‐on therapy) probably leads to higher adverse events incidence compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse eventsc ( · adult patients after liver transplantation.
Prostaglandin showed no clear difference in serious adverse eventsc ( compared with placebo or standard care (low certainty).
1 finding from 1 review
Adverse effects: headache · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ migraine · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ migraine compared with placebo (very low certainty).
1 finding from 1 review